Navigation Links
Genzyme Withdraws Bioenvision's European Filing of Evoltra(R) in Elderly AML Patients
Date:3/19/2008

nding the current product label into adult AML. Preliminary data has been accepted for presentation at ASCO this spring and a supplemental new drug application (sNDA) for clofarabine is expected to be filed in the second half of this year. It is possible that data from this study also could be considered for part of a new filing with EMEA.

Evoltra is currently indicated for the treatment of acute lymphoblastic leukemia (ALL) in pediatric patients who have relapsed or are refractory to at least two prior regimens. The withdrawal of the European application of Evoltra in adult AML has no consequences for patients enrolled in current clinical trials or compassionate use programs.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

This press release contains forward-looking statements, including the expected results of the data generated from clofarabine clinical trials, the presentation and use of this data to support regulatory filings, and t
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... (HZDR), the Vienna University of Technology and the ... nearly perfect semiconductor crystals into a silicon nanowire. ... very fast and multi-functional processing units can be ... The research results will be published in the ... considered the cornerstone of future chip technology, but ...
(Date:7/23/2014)... 2014  Having the right people at the table ... business growth and achieving clinical and operational goals. The ... Summit, July 20-22, 2014, in San Diego ... and healthcare experts discussing how partnerships have positively impacted ... & Chief Executive Officer of Cape Regional Medical Center ...
(Date:7/23/2014)... - BioAmber Inc. (NYSE: BIOA ), ... that the underwriters of its common stock offering ... additional 420,000 shares of common stock at the ... underwriting discounts and commissions, in connection with its ... of common stock, bringing the expected net proceeds ...
(Date:7/23/2014)... , July 23, 2014 China Cord Blood Corporation ... China,s leading provider of cord blood collection, laboratory testing, ... Group Limited ("Cordlife"), a multi-product healthcare company catering to the mother ... forces in assisting patients across the PRC, Singapore ... , India , the Philippines ...
Breaking Biology Technology:A crystal wedding in the nanocosmos 2MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 2China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 3China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 4
... Its Kind Instant Dissolve Powder Antacid Delivers Faster Relief, ... Increased Convenience and Great Taste, ... a $20 million integrated marketing campaign,for the new TUMS(R) QuikPak(TM), ... TUMS brand. The QuikPak campaign, part of,a larger new "Bring ...
... Follow, FREDERICK, Md., April 21 ... for ActiPatch(TM) for,kidney-compromised patients. BioElectronics Corporation, (Pink ... revolutionary drug-free,anti-inflammatory patch which accelerates healing., ... ibuprofen,(Advil, Motrin, Nuprin) and Naproxen (Aleve, Anaprox, ...
... DUBLIN, Calif., April 21 SuperGen Inc.,(Nasdaq: ... discovery, rapid,development and commercialization of therapies for solid ... release its 2008,first quarter financial results on Monday, ... of the Company,s financial results and,any revised outlook ...
Cached Biology Technology:New TUMS(R) QuikPak(TM) Campaign Offers Innovative Heartburn Relief with a Little Help from the Jetsons 2Maryland Approves Medicaid Reimbursement for ActiPatch(R) 2SuperGen to Announce 2008 First Quarter Financial Results April 28, 2008 2
(Date:7/23/2014)... fur seals, alongside decades of in-depth monitoring, has ... change on a population of top-predators. Published in ... that the seals have significantly altered in accordance ... with climate conditions. Despite a shift in the ... passing down through generations, leaving the population in ...
(Date:7/23/2014)... issued a high health risk warning for Yellowknife and ... due to forest fires. In the image taken ... along normal wind patterns. Fire is an obvious ... is not quite so obvious and its effects are ... fire (forest, brush, crop, structure, tires, waste or wood ...
(Date:7/23/2014)... people around the world have no access to clean ... 3.4 million people die from water-related diseases every year. ... making a contribution to solving this problem. Working with ... of the Functional Materials Laboratory, the 23-year-old spent a ... , "What makes our DrinkPure filter unique is that ...
Breaking Biology News(10 mins):Genetic study shows major impact of climate change on Antarctic fur seals 2Genetic study shows major impact of climate change on Antarctic fur seals 3ETH student develops filter for clean water around the world 2
... leaf has revealed the oldest known evidence of a macabre ... to turn them into zombies. The discovery has been ... Hughes, from the University of Exeter, who studies parasites that ... manner of animals are susceptible to the often deadly body ...
... from Mount Sinai School of Medicine have enhanced our ... conversion, the process in which food is converted into ... scientists gain atomic-level insight into how organisms synthesize their ... published in the August issue of PLoS Biology ...
... Mont. -- Researchers at Montana State University have ... for treating antibiotic resistant infections, fungal infections and viral ... to study such compounds. The technologies are ... The first technology involves an existing clinical drug ...
Cached Biology News:Fossil reveals 48-million-year history of zombie ants 2Mount Sinai researchers discover new mechanism behind cellular energy conversion 2Montana State University offers 6 new biomedical technologies for licensing 2Montana State University offers 6 new biomedical technologies for licensing 3Montana State University offers 6 new biomedical technologies for licensing 4
... Proteolytic degradation is critical to ... short-lived and regulatory proteins as important ... cellular metabolism, heat shock and stress ... surface receptors and ion channels, cell ...
... degradation is critical to the maintenance ... regulatory proteins as important and diverse ... heat shock and stress response, antigen ... and ion channels, cell cycle regulation, ...
... digital scanner serves as the spot-picking platform. ... standard rack positions on the tray, leaving ... plates on the remaining two racks.,The software ... by mouse-click on the scanned gel image. ...
...
Biology Products: